Business Standard

A COMMERCIAL FEATURE

What's this ?

Commercial Feature is a Business Standard Digital Marketing Initiative.

The Editorial/Content team at Business Standard has not contributed to writing or editing these articles.

For further information, please write to assist@bsmail.in

Intrexon & Johnson Matthey team up for production of peptide-based APIs

Though peptide-based APIs are highly useful, they are often costly & difficult to produce

BS B2B Bureau  |  Budapest, Hungary 

Research

Corporation, a leader in the engineering and industrialisation of biology to improve the quality of life and health of the planet, and Johnson Matthey, a global leader in science that enables cleaner air, improved health and more efficient use of natural resources, have entered into an exclusive collaboration focused on the development of microbial strains for fermentative production of peptide-based active ingredients (APIs).

Peptide-based are used as highly effective treatments in numerous therapeutic classes. However due to their structural complexity, peptides often are costly and difficult to produce, requiring specialised equipment and reagents and lengthy synthetic sequences with low chemical yields. 

Through the collaboration, will utilise its proprietary microbial hosts and fermentation processes for expression of peptides with high fidelity and titer. will concentrate on the strain generation, initial fermentation and downstream isolation, as well as purification of the target  Following this foundational work, (JM) will be responsible for product scale-up, formulation, and commercialisation. 

“Peptides are an important class of therapeutic agents and JM is pleased to be collaborating with the team in using their innovative biologically-based technologies to access these technically challenging Through their strain engineering capabilities, we believe there is significant potential for more efficient production of these important compounds,” commented Robert MacLeod, chief executive of JM.

Randal Kirk, chairman and chief executive officer of Intrexon, added, “As a leading provider of complex and services, JM is an ideal partner for this program. Their expertise and capacity, combined with Intrexon's powerful platform for the identification, design and engineering of production cells, should provide significant potential for more efficient production of such high-cost active ingredients."

Under the terms of the agreement, JM will have access to Intrexon's technologies and expertise for microbe-based fermentative production of specific target APIs, and will receive a technology access fee and reimbursement for all and development costs. The agreement also provides for milestone payments to Intrexon, as well as royalties based on net sales of commercialised products.

First Published: Mon, June 19 2017. 15:59 IST
RECOMMENDED FOR YOU

Intrexon & Johnson Matthey team up for production of peptide-based APIs

Though peptide-based APIs are highly useful, they are often costly & difficult to produce

Though peptide-based APIs are highly useful, they are often costly & difficult to produce
Corporation, a leader in the engineering and industrialisation of biology to improve the quality of life and health of the planet, and Johnson Matthey, a global leader in science that enables cleaner air, improved health and more efficient use of natural resources, have entered into an exclusive collaboration focused on the development of microbial strains for fermentative production of peptide-based active ingredients (APIs).

Peptide-based are used as highly effective treatments in numerous therapeutic classes. However due to their structural complexity, peptides often are costly and difficult to produce, requiring specialised equipment and reagents and lengthy synthetic sequences with low chemical yields. 

Through the collaboration, will utilise its proprietary microbial hosts and fermentation processes for expression of peptides with high fidelity and titer. will concentrate on the strain generation, initial fermentation and downstream isolation, as well as purification of the target  Following this foundational work, (JM) will be responsible for product scale-up, formulation, and commercialisation. 

“Peptides are an important class of therapeutic agents and JM is pleased to be collaborating with the team in using their innovative biologically-based technologies to access these technically challenging Through their strain engineering capabilities, we believe there is significant potential for more efficient production of these important compounds,” commented Robert MacLeod, chief executive of JM.

Randal Kirk, chairman and chief executive officer of Intrexon, added, “As a leading provider of complex and services, JM is an ideal partner for this program. Their expertise and capacity, combined with Intrexon's powerful platform for the identification, design and engineering of production cells, should provide significant potential for more efficient production of such high-cost active ingredients."

Under the terms of the agreement, JM will have access to Intrexon's technologies and expertise for microbe-based fermentative production of specific target APIs, and will receive a technology access fee and reimbursement for all and development costs. The agreement also provides for milestone payments to Intrexon, as well as royalties based on net sales of commercialised products.

image
Business Standard
177 22

Intrexon & Johnson Matthey team up for production of peptide-based APIs

Though peptide-based APIs are highly useful, they are often costly & difficult to produce

Corporation, a leader in the engineering and industrialisation of biology to improve the quality of life and health of the planet, and Johnson Matthey, a global leader in science that enables cleaner air, improved health and more efficient use of natural resources, have entered into an exclusive collaboration focused on the development of microbial strains for fermentative production of peptide-based active ingredients (APIs).

Peptide-based are used as highly effective treatments in numerous therapeutic classes. However due to their structural complexity, peptides often are costly and difficult to produce, requiring specialised equipment and reagents and lengthy synthetic sequences with low chemical yields. 

Through the collaboration, will utilise its proprietary microbial hosts and fermentation processes for expression of peptides with high fidelity and titer. will concentrate on the strain generation, initial fermentation and downstream isolation, as well as purification of the target  Following this foundational work, (JM) will be responsible for product scale-up, formulation, and commercialisation. 

“Peptides are an important class of therapeutic agents and JM is pleased to be collaborating with the team in using their innovative biologically-based technologies to access these technically challenging Through their strain engineering capabilities, we believe there is significant potential for more efficient production of these important compounds,” commented Robert MacLeod, chief executive of JM.

Randal Kirk, chairman and chief executive officer of Intrexon, added, “As a leading provider of complex and services, JM is an ideal partner for this program. Their expertise and capacity, combined with Intrexon's powerful platform for the identification, design and engineering of production cells, should provide significant potential for more efficient production of such high-cost active ingredients."

Under the terms of the agreement, JM will have access to Intrexon's technologies and expertise for microbe-based fermentative production of specific target APIs, and will receive a technology access fee and reimbursement for all and development costs. The agreement also provides for milestone payments to Intrexon, as well as royalties based on net sales of commercialised products.

image
Business Standard
177 22